

CLAIMS

1.- Use of IFN-alpha 5 or the gene sequence coding for it  
5 and/or essentially derived gene sequences for the  
manufacture of compositions useful in the treatment of  
liver diseases.

2.- Use according to claim 1, for the manufacture of  
10 compositions useful in the treatment of chronic hepatitis  
C.

3.- Use according to claim 1, for the manufacture of  
15 compositions useful in the treatment of cirrhosis of viral  
origin.

4.- Use according to claim 1, for the manufacture of  
20 compositions useful in the treatment of hepatocellular  
carcinoma.

5.- Use according to any one of claims 1-4, in which the  
25 manufactured composition is used to genetically induce  
physiological synthesis of interferon alpha 5, at nuclear  
level, in diseased liver cells deficient in that synthesis.

6.- Use according to any one of claims 1-4, in which  
30 manufacture of the composition comprises developing a  
recombinant protein for human application by cloning an  
expression vector in an appropriate host.

7.- Use according to claim 6, in which the cloned host is a  
eucaryote organism, preferably *Escherichia Coli*.

8.- Use according to claim 6, in which the cloned host is a procaryote organism, preferably *Solanum tuberosum*.

5 9.- Use according to any one of the foregoing claims, in which the manufactured composition is a composition which can be ingested with food.

10 10.- Use according to claims 1 to 4, characterised in that the manufactured composition is a composition for somatic gene therapy.

add  
(2)

add c<sup>2</sup>